Neurocrine Biosciences Reports Fourth Quarter and Year-End 20...(78 129 Interest income and...),Health

Date:2/3/2009

78 129 Interest income and expense, net (1,633) 616 (4,893) 4,814 Total other income 1,861 619 (1,315) 4,943 Net loss $(28,854) $(127,975) $(88,613) $(207,299) Net loss per common share: Basic and diluted $(0.75) $(3.35) $(2.30) $(5.45) Shares used in the calculation of net loss per common share: Basic and diluted 38,599 38,165 38,449 38,009 NEUROCRINE BIOSCIENCES, INC. Condensed Consolidated Statements of Operations (in thousands, except for per share data) December 31, December 31, 2008 2007 (unaudited) Cash, cash equivalents and marketable securities $80,473 $179,385 Other current assets 950 3,563 Total current assets 81,423 182,948 Property and equipment, net 6,191 82,598 Long-term investments 21,057 - Restricted cash 6,409 6,399 Other non-current assets 3,102 4,709 Total assets $118,182 $276,654 Current liabilities $26,094 $29,907 Long-term liabilities 55,314 19,305 Leaseback financing obligation - 108,745 Stockholders' equity 36,774 118,697 Total liabilities and stockholders' equity
'/>"/>

SOURCE Neurocrine Biosciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance